| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 |
| filingDate |
2016-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_283d53cde476a9109d8e45d93b739556
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb940d9fec34dc97f2cc48d99e820828
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_657cab0fad2c118012d4b48a589bb2e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94e9451b16ddbb3d695cdba5fa55ea33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1be3a947899a6ecdcd21613afb3d95a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dde3c9f2077e0373a5ad80416591f5a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_389d9b347a9a59f8d5ba3ba21a92fb2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0a5e2ea07e45f05fa3e64e4fce6d7d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cd7dff0805e7f6db6c5664c27a4b466
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe4a9f74d329d516723cd4d3754a5e8e |
| publicationDate |
2019-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10399968-B2 |
| titleOfInvention |
Hydroxyalkyl thiadiazole derivatives |
| abstract |
Problem to be Solved n There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. n Solution to the Problem n As a result of intensive research, the present inventors have found that a compound represented by general formula (I), n n n n n n n n n n n n a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10752647-B2 |
| priorityDate |
2015-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |